The Fly

HCA Healthcare price target raised to $283 from $239 at RBC Capital

RBC Capital analyst Ben Hendrix raised the firm’s price target on HCA Healthcare to $283 from $239 and keeps an Outperform rating on the shares. The company’s Q4 results were "solid" and its initial 2023 guidance reflects a core EBITDA growth assumption that is near the midpoint of historical ranges, the analyst tells investors in a research note. The firm is also adjusting the target enterprise value to expected EBITDA multiple in its model to 9.5-times from 9.0-times given HCA’s continued strong demand, along with its focus on capacity and cost management initiatives.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on HCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More